FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:67-69 July 5, 2007 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Home, P. D. PubMed Citation

In this issue of the Journal,¹ Home and colleagues report interim results from the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes, or RECORD, study (NCT00379769 [ClinicalTrials.gov] ). The RECORD study is a 6-year, open-label, noninferiority trial in which patients with type 2 diabetes who had inadequate glucose control with metformin or sulfonylurea alone were randomly assigned to receive rosiglitazone (Avandia) or the combination of metformin and sulfonylurea. The primary outcome was a composite of hospitalization and death from cardiovascular causes. As of March 2007, data were available on the 4447 patients randomly assigned to receive one of . . . [Full Text of this Article]

Source Information

From the Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, and the Center for Health Studies, Group Health, Seattle (B.M.P.); and the Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC (C.D.F.).

This article (10.1056/NEJMe078116) was published at www.nejm.org on June 5, 2007.

This article has been cited by other articles:

• Biserni, A., Giannessi, F., Sciarroni, A. F., Milazzo, F. M., Maggi, A., Ciana, P. (2008). In Vivo Imaging Reveals Selective Peroxisome Proliferator Activated Receptor Modulator Activity of the Synthetic Ligand 3-(1-(4-Chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886). Mol. Pharmacol. 73: 1434-1443 [Abstract] [Full Text]  
• (2008). Glitazones in type 2 diabetes: an update. DTB 46: 25-29 [Abstract] [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Grim, P., Hunkler, R. J., Hontz, K. M., Schumock, G. T. (2008). Projecting future drug expenditures--2008. Am J Health Syst Pharm 65: 234-253 [Abstract] [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2008). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetes Care 31: 173-175 [Full Text]  
• Diamond, G. A., Bax, L., Kaul, S. (2007). Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death. ANN INTERN MED 147: 578-581 [Abstract] [Full Text]